

Michael Byrne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3816039/publications.pdf>

Version: 2024-02-01

52
papers

1,213
citations

516710

16
h-index

395702

33
g-index

56
all docs

56
docs citations

56
times ranked

2176
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i>-rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	5.2	5
2	Reduction in the Prevalence of Thrombotic Events in Sickle Cell Disease after Allogeneic Hematopoietic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 277.e1-277.e6.	1.2	2
3	Association of Leukocyte Adhesion and Rolling in Skin With Patient Outcomes After Hematopoietic Cell Transplantation Using Noninvasive Reflectance Confocal Videomicroscopy. <i>JAMA Dermatology</i> , 2022, , .	4.1	1
4	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	1.2	15
5	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. <i>Blood</i> , 2021, 137, 751-762.	1.4	183
6	Similar Outcomes in Early-Failure Steroid-Dependent Compared to Upfront Steroid Refractory Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplant. <i>Journal of Hematology (Brossard, Quebec)</i> , 2021, 10, 35-39.	1.0	0
7	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	7.2	45
8	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
9	Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 927-931.	2.5	1
10	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 679.e1-679.e8.	1.2	10
11	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.	1.2	15
12	Cytomegalovirus immunoglobulin G: passive transfer or prior infection?. <i>British Journal of Haematology</i> , 2021, 195, 11-12.	2.5	0
13	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	2.4	13
14	Guideline for in vivo assessment of adherent and rolling leukocytes in human skin microvasculature via reflectance confocal videomicroscopy. <i>Microcirculation</i> , 2021, 28, e12725.	1.8	4
15	Detecting and preventing post-hematopoietic cell transplant relapse in AML. <i>Current Opinion in Hematology</i> , 2021, Publish Ahead of Print, 380-388.	2.5	0
16	Treosulphan versus busulphan: pros and cons. <i>British Journal of Haematology</i> , 2021, 195, 304-305.	2.5	1
17	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
18	Pituitary Apoplexy During Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e691-e693.	0.4	3

#	ARTICLE	IF	CITATIONS
19	The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1006-1014.	4.1	45
20	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. <i>Blood Advances</i> , 2020, 4, 2084-2094.	5.2	14
21	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
22	Improving the Odds. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e173-e174.	2.0	1
23	Indications for Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 268-275.	2.3	6
24	Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1137-1146.	2.4	7
25	Maintenance Strategies After Hematopoietic Cell Transplantation. <i>Pharmacotherapy</i> , 2020, 40, 727-740.	2.6	2
26	Individual cell motion in healthy human skin microvasculature by reflectance confocal video microscopy. <i>Microcirculation</i> , 2020, 27, e12621.	1.8	8
27	Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies. <i>Blood Advances</i> , 2020, 4, 586-598.	5.2	40
28	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
29	Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e344-e351.	2.0	59
30	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
31	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
32	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	5.2	71
33	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
34	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e46-e54.	2.0	24
35	Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 648-661.	2.4	14
36	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 662-673.	2.4	48

#	ARTICLE	IF	CITATIONS
37	Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 145-154.	2.0	16
38	Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Clinical Hematology International</i> , 2019, 1, 94-100.	1.7	5
39	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 932-937.	2.4	1
40	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 535-555.	2.4	75
41	Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. <i>Leukemia Research</i> , 2018, 65, 67-73.	0.8	12
42	Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2018, 53, 701-707.	2.4	16
43	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 228-241.	2.0	43
44	Leveraging JAK-STAT regulation in myelofibrosis to improve outcomes with allogeneic hematopoietic stem-cell transplant. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 251-259.	2.5	4
45	Defining Incidence and Risk Factors for Catheter-Associated Bloodstream Infections in an Outpatient Adult Hematopoietic Cell Transplantation Program. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2081-2087.	2.0	11
46	Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy. <i>Bone Marrow Transplantation</i> , 2018, 53, 1589-1592.	2.4	5
47	Successful Salvage with Inotuzumab Ozogamicin in Relapsed/Refractory Lymphoid Blast Crisis of Chronic Myeloid Leukemia after Failure of Multiple Lines of Therapy Including Blinatumomab. <i>Blood</i> , 2018, 132, 5452-5452.	1.4	3
48	Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia. <i>Blood</i> , 2018, 132, 4055-4055.	1.4	14
49	Making inroads to the cure: Barriers to clinical trial enrollment in hematopoietic cell transplantation. <i>Clinical Transplantation</i> , 2017, 31, e12948.	1.6	4
50	Peripheral blood stem cell versus bone marrow transplantation: A perspective from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Experimental Hematology</i> , 2016, 44, 567-573.	0.4	21
51	Hosting an Unruly Guest: The Impact of Late Acute and Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 779-780.	2.0	0
52	PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice. <i>Blood</i> , 2015, 126, 1585-1594.	1.4	26